Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/17577
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPitakchotiwan P.
dc.contributor.authorLinasmita P.
dc.contributor.authorBuppanharun J.
dc.contributor.authorUpapan P.
dc.contributor.authorWanthong N.
dc.contributor.authorTantisiriwat W.
dc.date.accessioned2022-03-10T13:17:39Z-
dc.date.available2022-03-10T13:17:39Z-
dc.date.issued2021
dc.identifier.issn1252208
dc.identifier.other2-s2.0-85117166101
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/17577-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85117166101&doi=10.35755%2fjmedassocthai.2021.10.13128&partnerID=40&md5=3aeef7a75cf8113598817e0d77dfcf2e
dc.description.abstractBackground: Recently, the authors had reported a case with abacavir hypersensitivity reaction (ABC-HSR), the first diagnosed patient at the HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC). There was no data regarding the incidence or prevalence of ABC-HSR previously reported in Thailand. Objective: To study the prevalence of ABC-HSR, the abacavir use pattern and the cost effectiveness for the routine human leukocyte antigen (HLA)-B*5701 screening before abacavir use by analyses of the MSMC data. Materials and Methods: All patients at the MSMC who were prescribed abacavir from October 1, 2010 to September 30, 2020 were retrospectively reviewed for ABC-HSR and the abacavir use pattern at the time when abacavir was started. The cost-effectiveness analysis was applied by analyzing the cost between the routine HLA-B*5701 screening before abacavir use and the HLA-B*5701 confirmation for ABC-HSR. The cost for the prevention of a case of ABC-HSR was defined. Results: There were total of 54 patients who were prescribed abacavir and only one ABC-HSR case diagnosed. The prevalence of ABC-HSR was 1.85%. The main reason for the abacavir prescription was a substitution for tenofovir (TDF) because of the TDF adverse effects (81.13%). The HLA-B*5701 screening before abacavir use was done in 26.42% at the MSMC. If all eligible patients were routinely screened for the HLA-B*5701 allele before abacavir use, the cost would be 54,000 Baht. The cost for the diagnosis and the management of the ABC- HSR case was 7,230 Baht. The cost for the prevention of a case of ABC-HSR was 46,770 Baht. Conclusion: The prevalence of ABC-HSR was low. The main reason for abacavir use was a substitution for TDF. The cost for the prevention for a case of ABC-HSR was 46,770 Baht which would be less if the cost for the HLA-B*5701 test was reduced. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND | 2021.
dc.languageen
dc.subjectabacavir
dc.subjectHLA B57 antigen
dc.subjecttenofovir
dc.subjectabdominal pain
dc.subjectallele
dc.subjectallergic reaction
dc.subjectArticle
dc.subjectCD4 lymphocyte count
dc.subjectcost effectiveness analysis
dc.subjectdrug efficacy
dc.subjectgene frequency
dc.subjectgenotype
dc.subjecthuman
dc.subjectHuman immunodeficiency virus infection
dc.subjecthyperlipidemia
dc.subjecthypersensitivity
dc.subjectkidney failure
dc.subjectliver toxicity
dc.subjectlymphocytopenia
dc.subjectmyalgia
dc.subjectnephrotoxicity
dc.subjectpharyngitis
dc.subjectprescription
dc.subjectprevalence
dc.subjectroot cause analysis
dc.subjectspirometry
dc.subjectsubstitution reaction
dc.subjectsustained virologic response
dc.subjectthorax radiography
dc.subjectvirus load
dc.titlePrevalence of abacavir hypersensitivity reaction and cost-effectiveness of hla b*5701 screening: A ten-year experience in the hrh princess maha chakri sirindhorn medical center
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationJournal of the Medical Association of Thailand. Vol 104, No.10 (2021)
dc.identifier.doi10.35755/jmedassocthai.2021.10.13128
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.